The US Centers for Disease Control and Prevention (CDC) has issued a warning about an increase in cases of human parvovirus B19, commonly known as “fifth disease,” particularly among young children. The announcement, made on August 13, highlights the rising incidence of this highly contagious respiratory infection.
Parvovirus B19 is a seasonal virus transmitted through respiratory droplets from individuals who may be asymptomatic or symptomatic. It is most often seen in young children but can affect individuals of all ages. The CDC notes that while parvovirus B19 is not under routine surveillance in the US and is not a notifiable condition, there has been a noticeable uptick in cases.
The infection typically presents with mild, flu-like symptoms such as muscle aches, fever, headache, and fatigue. In its second stage, it can lead to a distinctive facial rash known as a “slapped cheek,” as well as joint pain, swelling, and a general body rash. While the illness usually resolves on its own, and there is no specific treatment, symptom management can help alleviate discomfort.
For individuals with weakened immune systems or blood disorders, parvovirus B19 can cause more severe complications, including anemia. Pregnant women are also at risk, as the virus can be transmitted from mother to fetus, with a five to ten percent chance of adverse effects on the pregnancy, including miscarriage.
The CDC advises that individuals with parvovirus B19 can safely resume work or school once the rash appears, as the virus is most contagious in the early stages of the illness. General precautions, such as thorough hand washing and covering the mouth and nose with a mask, are recommended to prevent the spread of the virus. There are currently no vaccines available for parvovirus B19.
The recent increase in cases, particularly observed in 14 European countries earlier this year, underscores the need for vigilance and adherence to preventive measures to manage the spread of this infectious disease.
